SQZ Biotechnologies ROA 2020-2022 | SQZ

Current and historical return on assets (ROA) values for SQZ Biotechnologies (SQZ) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
SQZ Biotechnologies ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-12-31 $-0.08B $0.10B -50.31%
2022-09-30 $-0.08B $0.16B -40.94%
2022-06-30 $-0.08B $0.18B -36.19%
2022-03-31 $-0.07B $0.20B -32.53%
2021-12-31 $-0.07B $0.23B -27.98%
2021-09-30 $-0.07B $0.24B -30.30%
2021-06-30 $-0.06B $0.24B -28.13%
2021-03-31 $-0.06B $0.26B -32.79%
2020-12-31 $-0.05B $0.23B -50.00%
2020-06-30 $-0.03B $0.00B inf%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.024B $0.021B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $140.576B 8.70
GSK (GSK) United Kingdom $75.923B 9.52
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.436B 19.34
Ginkgo Bioworks Holdings (DNA) United States $2.549B 0.00
Arcus Biosciences (RCUS) United States $1.194B 0.00
Biohaven (BHVN) United States $0.913B 0.00
Emergent Biosolutions (EBS) United States $0.394B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.152B 0.00
Enzo Biochem (ENZ) United States $0.106B 0.00
Gelesis Holdings (GLS) United States $0.012B 0.00